Intravitreal injections of medications, particularly anti-vascular endothelial growth factors (anti-VEGF), are currently considered as one of the most common procedures in medicine to treat diseases such as neovascular age-related macular degeneration and diabetic macular edema1. The gene discussed is VEGFA; the disease is wet macular degeneration.